| Sara Lynne Simonson, PA-C | |
|
1012 E 2nd St, Duluth, MN 55805-2200 | |
| (218) 249-2450 | |
| (218) 249-2451 |
| Full Name | Sara Lynne Simonson |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 9 Years |
| Location | 1012 E 2nd St, Duluth, Minnesota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053565861 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 103577 (Minnesota) | Secondary |
| 363A00000X | Physician Assistant | 2300 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Lukes Hospital | Duluth, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Lukes Hospital Of Duluth | 7113834839 | 352 |
News Archive
Pearl Therapeutics Inc. today announced positive top-line results from a randomized, double-blind, Phase 2b, dose-ranging study of glycopyrrolate, a long-acting muscarinic agonist (LAMA) delivered twice a day (BID) via metered-dose inhaler in patients with moderate-to-severe COPD.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today it has signed a collaboration agreement with Transgene S.A. and ChronTech Pharma AB to evaluate a novel therapeutic vaccination strategy against genotype 1 hepatitis C virus in a phase I clinical study.
The first new projections of future aircraft emissions in 10 years predicts that carbon dioxide and other gases from air traffic will become a significant source of global warming as they double or triple by 2050. The study is in ACS' Environmental Science & Technology, a semi-monthly journal.
Shelly Peyton, a chemical engineer at the University of Massachusetts Amherst, is building working models of human bone, breast, liver and artery tissues to see how cells behave when they are affected by a disease such as cancer.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sara Lynne Simonson, PA-C 1012 E 2nd St, Duluth, MN 55805-2200 Ph: (218) 249-2450 | Sara Lynne Simonson, PA-C 1012 E 2nd St, Duluth, MN 55805-2200 Ph: (218) 249-2450 |
News Archive
Pearl Therapeutics Inc. today announced positive top-line results from a randomized, double-blind, Phase 2b, dose-ranging study of glycopyrrolate, a long-acting muscarinic agonist (LAMA) delivered twice a day (BID) via metered-dose inhaler in patients with moderate-to-severe COPD.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today it has signed a collaboration agreement with Transgene S.A. and ChronTech Pharma AB to evaluate a novel therapeutic vaccination strategy against genotype 1 hepatitis C virus in a phase I clinical study.
The first new projections of future aircraft emissions in 10 years predicts that carbon dioxide and other gases from air traffic will become a significant source of global warming as they double or triple by 2050. The study is in ACS' Environmental Science & Technology, a semi-monthly journal.
Shelly Peyton, a chemical engineer at the University of Massachusetts Amherst, is building working models of human bone, breast, liver and artery tissues to see how cells behave when they are affected by a disease such as cancer.
› Verified 7 days ago